吲哚胺2双加氧酶1在肿瘤免疫治疗中的研究进展-药学学报.PDF

药学学报 Acta Pharmaceutica Sinica 20 18, 53 (8): 1271 1278 ·1271 · 哚胺2,3-双加氧酶 1 在肿瘤免疫治疗中的研究进展 杜婷婷, 来芳芳, 陈晓光* ( 中国医学科学院、北京协和医学院 物研究所, 天然药物活性物质与功能国家重点实验室, 北京 100050) 摘要: 吲哚胺2,3-双加氧酶 1 (indoleamine 2,3-dioxygenase 1, IDO1) 是与肿瘤免疫机制密切相关的免疫检查 点之一。众多研究表明, IDO1 在乳腺癌、结直肠癌和肝癌等肿瘤组织中异常表达, 通过多种途径参与肿瘤免疫 逃逸机制。因此, 本文旨在阐述IDO1 的生物学功能及其在肿瘤逃逸中的重要作用, 并 绍目前在临床研究阶段 的IDO1 抑制剂进展情况。 关键词: 吲哚胺2,3-双加氧酶 1; 免疫治疗; 肿瘤逃逸 中图分类号: R967 文献标识码: A 文章编号: 0513-4870 (20 18) 08- 1271-08 Research progress of indoleamine 2,3-dioxygenase 1 in tumor immunotherapy * DU Ting-ting, LAI Fang-fang, CHEN Xiao-guang (State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Ac ademy of Medical Sciences and Peking Union Medical College, Beijing 100050, China ) Abstract : IDO1 (indoleamine 2,3-dioxygenase 1) is one of the most significant checkpoint in tumor immunology. Numerous studies indicates that IDO1 is abnormally expressed in breast cancer, colorectal cancer, liver cancer and other tumor tissues, participating in tumor immune escape through multiple pathways. This review is prepared to elucidate the biological function of IDO1, highlight its pivotal role in tumor evasion, and summarize IDO1 inhibitors in the clinical trials. Key words: indoleamine 2,3-dioxygenase 1; immunotherapy; tumor escape 近年来, 随着肿瘤免疫逃逸机制相关研究的逐 疗黑色素瘤、头颈部肿瘤和霍奇金淋巴瘤等, 是程序 渐深入, 肿瘤免疫治疗进入了人们的视野。嵌合抗原 性死亡配体 1 (programmed death-ligan